)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Foghorn Therapeutics (FHTX) investor relations material
Foghorn Therapeutics 8th Annual Targeted Protein Degradation & Induced Proximity Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.8th Annual Targeted Protein Degradation & Induced Proximity Summit summary30 Oct, 2025
Strategic pipeline and R&D overview
Focused on drugging the chromatin regulatory system, targeting previously undruggable cancer drivers with selective protein degraders.
Advanced a portfolio including ARID1B, CBP, and EP300 degraders, with FHD-909 (SMARCA2 inhibitor) in phase 1 trials via a Lilly partnership.
Emphasized a biology-first approach, leveraging deep mechanistic understanding and integrated platform capabilities.
FHD-909 trial enrolling well in the US and Japan, with dose expansion decisions expected in H1 2026.
Pipeline aims for multiple value inflection points, with IND-enabling studies for new programs targeted for 2026.
ARID1B degrader program
Achieved robust, selective ARID1B degradation, sparing ARID1A and other BAF complex members.
Targeting cancers with ARID1A mutations, present in up to 5% of solid tumors, including endometrial, gastric, bladder, and NSCLC.
In vivo proof-of-concept anticipated in 2026; high selectivity confirmed via proteomic analysis.
Structural biology insights enabled improved degrader design and target gene modulation.
Positive industry feedback received at the TPD and Induced Proximity Summit.
Selective CBP degrader program
CBP degrader (CPPD171) shows efficacy in EP300 mutant cancers and ER-positive breast cancer models.
Demonstrated complete tumor regression in gastric cancer models with no significant platelet impact.
Long-acting injectable formulation allows for weekly or biweekly subcutaneous dosing.
Non-GLP tox studies initiated; IND readiness targeted for 2026.
Basket trial approach considered for diverse tumor histologies; separate study for ER-positive breast cancer likely.
ARID1A mutation characterization for patient selection?
EP300 degrader combinability with other agents?
CBP long-acting formulation: API change or tuning?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Foghorn Therapeutics earnings date
Q3 202510 Nov, 2025
Next Foghorn Therapeutics earnings date
Q3 202510 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies targeting the chromatin regulatory system, which plays a critical role in gene expression and cellular identity. The company leverages its proprietary Gene Traffic Control platform to gain an integrated understanding of how chromatin regulation affects disease, enabling it to identify and develop potential drug candidates. Foghorn's research focuses on treating genetically determined dependencies in various cancers, including hematologic malignancies and solid tumors. The company has collaborations with major pharmaceutical firms to further its therapeutic pipeline. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage